0.02
—
Close of 6 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About SQZ Biotechnologies
Its shares trade under the ticker SQZB. It has been listed since 30 October 2020. In the fiscal year to 31 December 2023, it reported revenue of $12.2m and a net loss of $71.6m.
SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. The company is headquartered in Watertown, Massachusetts. The company went IPO on 2020-10-30. The firm is focused on unlocking the full potential of cell therapies to benefit patients. In oncology, it is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. Its clinical-stage cell therapy candidates include SQZ Enhanced APC (eAPC) Platform, SQZ Activating Antigen Carrier (AAC) Platform and SQZ Tolerizing Antigen Carrier (TAC) Platform. The SQZ eAPC platform is the second-generation product candidate designed to generate tumor specific CD8+ T cell activation to drive the antitumor immune response. The SQZ AAC platform is designed to induce antigen presentation in vivo by deriving antigen carriers from engineering red blood cells (RBCs) with tumor specific antigens and adjuvants. Its SQZ TAC platform is designed to induce antigen-specific immune tolerance in vivo by utilizing a similar approach to the AAC platform.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Oct 2020
- Employees
- 53
- Website
- sqzbiotech.com ↗
Leadership
Pay as last reported
- Dr. Bernard CoulieIndependent Non-Executive Chairman of the Board$94,400
- Dr. Howard BernsteinInterim Chief Executive Officer, Director, since 2015$1.6m
- Mr. David FirstChief People Officer
- Mr. Richard CapassoChief Accounting Officer
- Mr. Lawrence KnopfGeneral Counsel$944,031
- Dr. Marshelle WarrenChief Medical Officer$775,977
- Ms. Amy SchulmanDirector, since 2015$104,400
- Dr. Paul BolnoIndependent Director$94,400
- Mr. Marc EliaIndependent Director$86,900
- Mr. Pushkal GargIndependent Director$94,400
- Dr. Klavs JensenIndependent Director$89,400
- Dr. Marc SchegerinIndependent Director$94,400
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 29
- Environment
- 18
- Social
- 56
- Governance
- 12
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- SQZ Biotechnologies Co employs 53 full-time staff members in the US.
- The company developed the SQZ Enhanced APC Platform for cancer treatment.
- The firm focuses on unlocking cell therapy potential for serious conditions.
Weaknesses
- The company has only 53 employees which limits operational capacity.
- The SQZ AAC platform relies on engineering red blood cells.
- The business description cuts off before detailing the TAC platform fully.
Opportunities
- The SQZ TAC platform aims to induce immune tolerance in vivo.
- Cell therapies can benefit patients with infectious diseases and cancer.
- The eAPC platform generates tumor-specific CD8+ T cell activation.
Threats
- The company went public on 30 October 2020 in the US.
- Competitors in the biotechnology sector may develop similar antigen platforms.
- Clinical-stage candidates face risks during regulatory approval processes.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.